(P01-051-20) Dietary Supplementation with a Low Dose of Finasteride Does Not Alter the Lipid Profile of Ldlr-Deficient Mice
Objectives: Androgenic alopecia is characterized by a receding hairline and hair loss from the frontal scalp. This genetic condition affects approximately 80% of men and 42% of women. Finasteride is the only oral treatment currently approved by the FDA to prevent and treat androgenic alopecia, and it is currently prescribed to over nine million males in the US. Recent claims suggest that long-term use of finasteride could have detrimental health effects by affecting the lipid profile in people. Finasteride prevents the conversion of testosterone to its active metabolite dihydrotestosterone by inhibiting the type II 5alpha-reductase, which is predominantly present in the hair follicle and the prostate. As a result, finasteride alters the systemic levels of testosterone and its derivative estradiol. Hormone homeostasis affects plasma lipid levels, therefore we hypothesize that supplementation with finasteride will affect systemic lipid profile in atheroprone low-density lipoprotein receptor (Ldlr-/-) mice fed a Western diet (high cholesterol, high fat).
Methods: We fed six-week-old male Ldlr-/- mice (10/group) fed a Western diet (control) or a Western diet supplemented with 10 mg Finasteride/kg diet for 12 weeks. We monitored body weight progression and food intake during the entire experiment. A week before harvesting the tissues, mice were fasted overnight to perform a glucose tolerance test. At the moment of sacrifice, final body weight and several tissues were collected such as the inguinal, retroperitoneal, and gonadal adipose tissues, skeletal muscle (gastrocnemius), and liver. Plasma was harvested to determine total cholesterol and triglyceride levels.
Results: Our data show that 12-week supplementation with a low dose of finasteride does not have a significant impact on food intake, body weight, or adiposity index. We did not observe any significant change in plasma lipids or glucose tolerance.
Conclusions: A low dose of finasteride supplemented for 12 weeks does not alter the lipid profile in the atheroprone Ldlr-/- mouse model, nor alters adiposity index. These data indicate that finasteride does not have detrimental effects on these metabolic parameters.
Funding Sources: U.S. Department of Agriculture (Multi-State grant project W4002)
James P. McQueen
University of Illinois at Urbana-Champaign Urbana, Illinois
Assistant Professor University of Illinois at Urbana-Champaign urbana, Illinois